ArticleTransfusion2025
A spleen is required for antibody mediated immune enhancement but not for RBC clearance or antigen-modulation in mice.
Article in Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effects of SupergroundAnimals : an open access journal from MDPI · 2025Article
- A spleen is required for antibody mediated immune enhancement but not for RBC clearance or antigen-modulation in mice.Transfusion · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIgG against alloantigens on transfused RBC can lead to antibody-mediated immune enhancement (AMIE). AMIE has properties not found in other forms of alloimmunization, including rapid clearance of RBCs, a requirement for Fc-gamma receptors on dendritic cells, and no dependence on IFNAR. A spleen is required for alloimmunization to transfused RBCs under normal conditions but its role in AMIE has not been assessed. STUDY DESIGN AND
methodsMice with surgical splenectomy or sham surgery were infused with monoclonal IgG against model antigens (HOD or KEL) followed by a transfusion of respective transgenic RBCs. Antibody binding to transfused RBCs, antigen-modulation, and RBC clearance were assessed by flow cytometry. IgM and IgG to the HOD and KEL alloantigens were quantified by flow cytometry-based crossmatch.
resultsIgG to either HOD or KEL caused brisk clearance of RBCs with almost complete antigen modulation at 24 h and a strong enhancement of both IgM and IgG in sham-operated animals. In splenectomized animals, AMIE was eliminated; antigen-modulation occurred but with decreased kinetics and magnitude; and RBC clearance was the same as in sham animals.
conclusionsThe current study extends the role of spleen as a general requirement for all known pathways of RBC alloimmunization studied thus far. However, the dissociation of clearance and antigen-modulation from AMIE shown in the current study raises the possibility that antigen-modulation and AMIE are correlated due to a confounding common cause (i.e., IgG binding RBCs).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.